Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 06:40PM GMT
Release Date Price: $75.91
Eliana Merle;Cantor Fitzgerald;Co.;Analyst

&; -

Hey, guys. I'm Ellie Merle. I'm one of the biotech analysts here at Cantor. Very happy to have BioMarin here with us today at the Cantor conference. Guys, thanks so much for joining us here. With us from BioMarin is Hank Fuchs, President, Worldwide R&D; as well as Brian Mueller, Executive Vice President, Chief Financial Officer. Thanks so much for joining us today.

Questions & Answers

Eliana Merle;Cantor Fitzgerald;Co.;Analyst

&; -

Maybe before I dive into questions, maybe, Brian, can you frame for us, not starting with Valrox, where we are with the base business and your confidence in sort of the sustainability and long-run sort of cash generation from this business?

Brian R. Mueller
BioMarin Pharmaceutical Inc. - Executive VP & CFO

Yes. Thanks, Ellie. Thanks for having us, and thanks for the question. So that's one of the key, I think, considerations, especially

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot